Clinical Trial Update: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing [NA]

View source ↗

Summary

A clinical trial update noting ongoing recruitment for monitoring patients with HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibito…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Cancer, Cancer of the Breast | NA | Status: RECRUITING